growth, spread, and clinical behavior of lymphoid malignancies. In a mouse model system using lymphoma cells, LFA-1 expression could be related to an increased metastatic potential of such cells in vivo. 13 In human lymphomas, LFA-1 expression is found on tumor cells in low-and medium-grade malignant while absence of LFA-1 seems to be a characteristic of high-grade malignant lymphoma^.'^,'^ The presence of LFA-1 has been related to the aggressiveness and anatomical site of the t~m o r '~. '~ and its absence might contribute to an escape from immunosurveillance.'".' ' Given the differential expression of LFA-1 in lymphomas, we studied whether malignant plasma cells in MM express LFA-1 and whether the expression of this adhesion molecule correlated with the proliferation of the plasma cells as the hallmark of the disease.
MATERIALS AND METHODS
Forty-four patients with multiple myeloma (MM) and six with monoclonal gammopathies of undetermined significance (MGUS) were included in this study. MM was diagnosed at the time of bone marrow sampling according to the Southwest Oncology Group (SWOG) criteria." MGUS patients showed a stable M-component for at least 2 years. According to the Durie and Salmon staging system, one patient was stage Ib, three stage IIa, 39 stage IIIa, and one stage IIIb. The isotypes of the serum monoclonal immunoglobulins in the various patients were two IgM, 28 IgG, 10 IgA, two IgD, and eight Bence Jones protein. The median age (MM and MGUS patients) was 60.1 years, ranging between 43 and 81; 22 were men and 28 were women.
The patient population was divided into three groups according to clinical performance and M-protein level. The first group included patients with nonactive disease having no or mild clinical symptoms and no increase in M-protein 3 months before or after the time of analysis. The second group contained the patients with active, symptomatic disease, including bone pain and an increase in M-protein in the 3 months before analysis. The third group consisted of patients with rapidly progressive disease, characterized by severe bone pain, hypercalcemia, and pancytopenia; in these patients, a decrease in M-protein production is obsewed (fulminant myeloma). In the third group, 12 patients progressed into a fulminant phase after a relatively benign disease course, and two patients already presented with fulminant disease. The mean labeling index (LI) in the three MM groups defined above were 0.6%, 1.4%, and 8.8% for the nonactive, active, and fulminant MM
Patients.
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group, respectively. The median time of follow-up in these three MM groups was 26 months for nonactive MM (range, 12 to 36), 16 months for active MM (range, 0 to 36), and 24 months for fulminant MM (range, 0 to 40). The Characteristics of the patients with MGUS and the three groups of MM are summarized in Table  1 .
Bone marrow cells of patients were isolated for diagnostic reasons by Ficoll-Isopaque (Pharmacia, Uppsala, Sweden) density centrifugation of bone marrow aspirates. In addition, bone marrow cells from healthy individuals were analyzed.
Cells were washed twice in minimal essential medium (MEM) containing penicillin (100 IU/mL) and streptomycin (100 pg/mL) and used for immunofluorescence analysis (see below) or stored frozen for later analysis. Peripheral blood monocytes were purified from the Ficoll-Isopaque density centrifugation isolated mononuclear cell fraction by adherence to plastic dishes. The human plasmacytoma cell line CRL 1484''~~ was maintained in RPMI-1640 supplemented with 10% fetal calf serum (FCS; GIBCO, Paisley, UK), glutamine (2 mmol/L), penicillin (100 IU/mL), and streptomycin (100 pg/mL) at 37°C in a 5% CO, humidified atmosphere. The effector cell line used for the cytotoxicity assay (see below) was AK4 (TCRy6), an alloreactive cytotoxic T-cell clone (CTL)?1,22 The target cell line was APD, an Epstein-Barr virus (EBV)-transformed B-cell
The cell lines were free of mycoplasma contamination, which was determined as described by Spierenburg et al."
Cells and cell lines. 
Monoclonal antibodies (MoAbs).
The CDlla MoAbs used in this study were F8.8 (see below), SPV-L7 (Monosan, Uden, The Netherlands), and CLB-LFA-1/2 (CLB, Amsterdam, The Netherlands). In addition, the following CD antigens were analyzed: CDllb (CLB-modgran-1; CLB), CD38 (OKT-10; Ortho, Raritan, NJ), CD20 (Bl; Coulter, Mydrecht, The Netherlands), CDlO (CALLA, Becton Dickinson, Erembodegem, Belgium), CD3 (Leu-4, Becton Dickinson), and CD13 (MY7; Coulter). Antibromodeoxyuridine (a-BrdU) fluorescein isothiocyanate (FITC)-conjugated MoAb (Becton Dickinson) was used to determine the LI of the plasma cells (see below).
Production of the F8.8 MoAb. Six-week-old BALB/c mice were immunized twice, intrasplenically, with 2 x 10s cells of the surface IgM-negative EBV cell line F18B2, with a 1-week interval. Three days after the last immunization, splenic cells were fused as described previously.24 IgG-containing hybridoma supematants were tested for their ability to inhibit homotypic adhesion of the EBV cell line N103 as described by Rothlein et al.= The hybridoma selected this way (F8.8) was cloned twice by limiting dilution and injected intraperitoneally in pristane-primed mice for ascites production. IgG was isolated by protein A chromatography and the subclass was determined using goat anti-mouse IgG subclassspecific antibodies (SBA, Birmingham, AL) as described by Koolwijk et a1.%
The analysis of the surface phenotype and the nature of the heavy and light chains present in the cytoplasm of the plasma cells using double immunofluorescence microscopy (DIFM) has been described elsewhere." In addition, bone marrow aspirates containing more than 50% CD38+ plasma cells were analyzed by flow cytometry28 (FACScan, Becton Dickinson). For this purpose, cells were sequentially incubated with OKTlO (CD38), FITC-labeled goat anti-mouse IgG antibodies (Becton Dickinson), and blocked with normal mouse serum followed by incubation of biotinylated MoAb (CDlla, CD10, CD20, or CD13) and streptavidin coupled to phycoerythrin (Becton Dickinson). LFA-1 expression on T cells in peripheral blood was analyzed by flow cytometry in a double-staining procedure as described above, using the anti-CDlla MoAbs F8.8, CLB-LFA-1/2, or SPV-L7 and biotinylated CD3 MoAb. The procedure for the biotinylation of MoAbs was performed exactly as described by Heitzmann and Richards." The phenotype of the plasma cells of the cell line CRL 1484 was analyzed by flow cytometry as described above.
The method to determine the LI of the bone marrow plasma cells has been described elsewhere.M In short, cells were incubated with 10 pmol BrdU. After fixation in suspension with 70% ethanol and partial DNA denaturation with 4N HCI, the cells were cytocentrifuged and subsequently stained with FITC-conjugated anti-BrdU MoAb and tetramethylrhodamine isothiocyanate (TR1TC)-conjugated, affinitypurified goat antibodies directed against human heavy or light chains (SBA).
Cytotoxicity was measured in a standard chromium release assay in a U-bottom, 96-well plate using complete medium. Briefly, varying numbers of effector cells (AK4) in 100 pL were mixed with 50 pL of diluted antibodies or for control values 50 pL medium in the wells of the plate. After 30 minutes, "Cr-labeled target cells (APD, 2 x l@/well) in 50 pL were added. Plates were centrifuged for 3 minutes at 100 x g and incubated for 3.5 hours at 37", 5% CO,. Plates were centrifuged again and released 5'Cr in 100 pL supernatant was measured in a gammacounter (Minaxi, Auto-gamma counter, Packard, Warrenville, Downers Grove, IL). All tests were performed in triplicate. The percentage of specific "Cr release was determined as: (experimenImmunofluorescence studies.
Determination of the labeling index.
Cyiotoricity assay.
2070 tal release -spontaneous release)/(total Triton-Xl Winduced release -spontaneous release) x 100.
Iodination and precipitation using the plasmacytoma cell line CRL 1484 was performed as described by Schwartz-Albiez et al." In short, cells were labeled with lUl (Amersham, Aylesbury, UK) in the presence of lactoperoxidase by pulses with hydrogen peroxide and subsequently solubilized in lysis buffer. After removing nuclei and cell debris by centrifugation, the cell lysate was cleared by preadsorptions with protein A-Sepharose CL4B (Pharmacia Fine Chemicals) and affinity-purified rabbit anti-mouse IgG and IgM antibodies (Dakopatts, Uithoorn, The Netherlands). To examine the specificity of the F8.8 MoAb for CDl la, sequential immunoprecipitation was performed. The lysate was divided in three aliquots. Aliquot I was precleared three timeswith a combination of 20 pgof rabbit anti-mouse IgG plus IgM, 100 pL protein A-Sepharose CL-4B, and 10 pgof the F8.8 MoAb, followed by immunoprecipitation with 10 pg of the anti-CDlla MoAb SPV-L7 or the CD38 MoAb OKT-I0 as a positive control. Aliquot I1 was treated identically, except the lysate was precleared with the MoAb SPV-L7 and subsequently immunoprecipitated with the F8.8 MoAb or OKT-10. Aliquot Ill was precleared with an isotype-and subclass-matched control MoAb, followed by immunoprecipitation with the MoAb F8.8 or SPV-L7.
CDlla and C D l l b were precipitated from I'3-labeled peripheral blood monocytes using protein A-Sepharose CL4B, rabbit anti-mouse IgG plus IgM, and the MoAb F8.8 or CLB-mon/gran-1, respectively.
After extensive washing, samples were boiled in sample buffer and subjected to polyacrylamide slab gel electrophoresis under reducing conditions (sodium dodecyl sulfate [SDSI-PAGE, 7.5%) according to Laemmli." Dried gels were visualized by exposure to x-ray films using intensifying screens. Table 3 ). Precipitation with the MoAbs F8.8 and CLB-LFA-1/2 shows two bands of approximately 180 and 95 Kd corresponding with the a-and P-chain of the LFA-1 molecule (Fig 1, lanes 5 and 6) . The LFA-1 specificity of the F8.8 MoAb was confirmed in sequential immunoprecipitation with the CLB-LFA-1/2 MoAb. Immunoprecipitation with either one of the anti-CDlla MoAbs depleted the cell lysates of LFA-1 that could not be precipitated any more with the other antibody (Fig 1, lanes 2 and 4) .
Cell surface iodination and immunoprecipitation.
RESULTS
The
CD18 reactivity of F8.8 was excluded by performing precipitation studies using '=I-labeled monocytes expressing CDlla/CD18 and CDllb/CD18. The F8.8 MoAb only precipitates bands corresponding to the CDl la and CD18 chains (Fig 2, lane 2 ) and no CDllb (Fig 2, lane 3) . These results prove that F8.8 recognizes the a-chain (CDlla) of the LFA-1 molecule.
Interference in the LFA-l/ICAM-1 interaction pathway partially inhibits the activity of CTLs.)' Inhibition of the spontaneous cytolysis of the EBV-transformed B-cell line APD by the CTL clone AK4 by anti-CDlla MoAb F8.8 is as effective as the reference MoAb SPV-L7 (Table 2 ). This strengthens the evidence that the F8. blood T lymphocytes results in comparable fluorescence patterns and intensities (Fig 3A) , the F8.8 MoAb proved to be superior in staining CDl la on plasma cells as compared with the MoAbs SPV-L7 and CLB-LFA-112. This is exemplified in Fig 3B, where the flow cytometric analysis of the CDlla expression on CD38' plasma cells of four representative MM patients is shown. Highest fluorescence intensities are obtained with the F8.8 MoAb. Furthermore, the histograms show that a considerable variation in LFA-1 expression on plasma cells is observed between individual patients. Plasma cells of patients K. and M. (Fig 3B-1 and B-3) are brightly stained, while plasma cells of patients B. and F. (Fig 3B-2 and B-4) only show a moderate LFA-1 expression. However, in all patients, staining with the F8. 8 MoAb results in the highest LFA-1 fluorescence intensity.
The patients with MM were divided into three groups based on clinical performance and M-protein level (see Methods). In the first group of MM patients (nonactive disease, n = 8), two patients could be identified as having low percentages of LFA-l+ plasma cells in their bone marrow. In the second group (active disease, n = 22), LFA-1' plasma cells were detected in 10 patients. In this group, two patients had a LFA-I apression and clinical disease. F8.8 (-) , and an isotype-and subclass-matched MoAb ( -) as a negative control. (B) Flow cytometric analysis of LFA-1 expression on bone marrow-derived CD38' plasma cells of MM patient K. (Fig 38-1) . patient B. (Fig 38-21 . patient M. (Fig 38-3) . and patient F. (Fig 38-4) using the anti-CD11a MoAbs SPV-L7 (---I, high percentage of LFA-I+ plasma cells (23.4% and 30.3%). Interestingly, the tumors of these patients also had a high LI (5 and 8, respectively). In the bone marrow samples of all patients with fulminant disease (group 3, n = 14), moderate to high percentages of LFA-l+ plasma cells were present. Figure 4 shows the plasma cell LFA-1 expression A relation was found between both parameters; plasma cell LFA-1 expression was preferentially found in patients who had tumors with large growth fractions (Fig 5 ) .
To investigate whether CDlla expression on plasma cells could be related to an aberrant phen0type,9~*" the expression of CD10, CD20, and CD13 on CD38' plasma cells was determined in MM patients with nonactive, active, and fulminant disease. In Table 3 , representative results are shown of these analyses, which indicate that no apparent correlation exists between plasma cell LFA-1 expression and the phenotype of the tumor cells.
LFA-1 expression and LI in MM.
Phenotyge and CDlla enpression. 
DISCUSSION
In recent years, it has become clear that adhesion molecules play a pivotal role in mediating cellular contact. Studies on the expression of such molecules on tumor cells in lymphoid malignancies increase our knowledge about their ability to interact with themselves or other cell types, and in this way contribute to our understanding of tumor growth and spread. In MM, ICAM-1 is expressed on all plasma ~e l l s ,~~,~' while recently the expression of CD56 (N-CAM) on aberrant plasma cells has been described." In some cases of MM, LFA-1 expression has been rep~r t e d , '~,~~,~~ in contrast to normal plasma cells which do not express this adhesion molecule.
In this study, we have investigated the presence of the adhesion molecule LFA-1 (CDlla/CD18) on plasma cells of normal individuals and patients with plasma cell dyscrasias. CDlla expression was detected on plasma cells from LFA-1 posltive plaamscella (K) . _ LFA-1 expression was analyzed by double immunofluorescence microscopy and additionally by FACS analysis if more than 50% monoclonal plasma cells were detected in the bone marrow aspirates. Both analyses were routinely performed with a panel of anti-CDlla MoAbs. Both the results from the fluorescence microscopy and the flow cytometric analyses showed that the F8.8 MoAb proved to be superior in staining plasma cells as compared with the reference anti-CDlla MoAb (see Fig 3B) . The specificity of F8.8 was extensively studied. In immunoprecipitation studies, we showed that F8.8 recognizes the a-subunit of the LFA-1 molecule (CDlla). Furthermore, F8.8 inhibited T-cell-mediated cytotoxicity to the same extent as the reference anti-CDlla MoAb. Taken together, these results prove that F8.8 binds to CDlla.
The observed difference in LFA-1 fluorescence intensity when plasma cells are stained with different anti-CDlla MoAbs is intriguing and might relate to glycosylation of the LFA-1 molecule. Electrophoretic analysis of the LFA-1 molecule in different lymphocyte subsets showed multiple glycosylated isoforms of the a-and p-chain, most likely as a result of different degrees of sialization.40 Although all three anti-CDlla MoAbs used in this study are equally capable of binding LFA-1 on unstimulated T lymphocytes (see Fig 3A) , it is possible that due to differences in glycosylation the isoform expressed on plasma cells is more efficiently recognized by F8.8 as compared with the other two anti-CDlla MoAbs.
The LFA-1 expression on CD38' bone marrow-derived plasma cells could not be related to the phenotype of the cells. No relation was found between LFA-1 expression and expression of the myelomonocytic antigen (CD13) and/or B-cell lineage antigens (CD20, CDlO). These results argue against the existence of a relation between LFA-1 expression and stage of differentiation of the malignant cells in MM and indicate that LFA-1 can be expressed on these plasma cells.
Not much is known about the regulation of LFA-1 protein expression in lymphoid cells. Recently, rus oncogene activation has been implicated in the selective upregulation of the expression of the a-chain of the LFA-1 molecule in EBV-transformed B cells.4' Whether similar processes are responsible for LFA-1 expression on the malignant plasma cells in MM, which are found to harbor rus mutations:' remains to be elucidated.
The results presented here indicate a novel correlation between LFA-1 expression on plasma cells of patients with MM and plasma cell proliferation. This relation suggests an involvement of this adhesion molecule in cellular interactions resulting in plasma cell proliferation. As plasma cells constitutively express ICAM-136 and this molecule can be induced on bone marrow adherent cells," one can envisage a mechanism in which the LFA-l/ICAM-1 adhesion pathway mediates adhesion among plasma cells, as well as with cells in the bone marrow microenvironment. Since lymphokines are important in plasma cell gro~th,"~' LFA-1-mediated intimate cellular contact between plasma cells and lymphokine-producing cells might be a critical event in the regulation of plasma cell growth in MM. Therefore, studies on functional aspects and regulation of the expression of adhesion molecules involved in such cellular interactions will contribute to our understanding of the pathophysiology of the disease process.
